Amfetamine and methylphenidate medications for attention-deficit/ hyperactivity disorder: Complementary treatment options

131Citations
Citations of this article
239Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders among school-aged children. It is highly symptomatic and associated with significant impairment. This review examines the role of stimulant medications in the treatment of children and adolescents with ADHD. Published clinical studies that compared methylphenidate- and amfetaminebased stimulants in children and adolescents with ADHD support the therapeutic utility of stimulant treatments, and suggest robust efficacy and acceptable safety outcomes in groups treated with either stimulant. Evidence-based guidelines agree that each patient with ADHD is unique and individual treatment strategies that incorporate both drug and non-drug treatment options should be sought. In seeking to optimize individual response and outcomes to stimulant therapy, important considerations include the selection of stimulant class, the choice of long- or short-acting stimulant formulations, addressing effectively any emergent adverse effects and strategies aimed at enhancing adherence to dosing regimen and persistence on therapy. © The Author(s) 2012.

Cite

CITATION STYLE

APA

Hodgkins, P., Shaw, M., Coghill, D., & Hechtman, L. (2012). Amfetamine and methylphenidate medications for attention-deficit/ hyperactivity disorder: Complementary treatment options. In European Child and Adolescent Psychiatry (Vol. 21, pp. 477–492). https://doi.org/10.1007/s00787-012-0286-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free